CLINICAL ROLE -
Riluzole Shows No Efficacy as a Neuroprotective Agent in Patients with Early-Stage Relapsing Remitting Multiple Sclerosis
Negative findings were reported for both clinical and imaging measures in a Phase II randomized trial of riluzole in comparison to placebo in patients with very early multiple sclerosis (MS).
Read More